



**FOR IMMEDIATE RELEASE**

**CAMBRIA BIOSCIENCES, DOW AGROSCIENCES ANNOUNCE MULTIYEAR COLLABORATION TO DEVELOP NEUROACTIVE INSECTICIDES**

**WOBURN, MA and INDIANAPOLIS, IN - October 28<sup>th</sup>, 2002** - Cambria BioSciences and Dow AgroSciences, LLC, a subsidiary of The Dow Chemical Company (NYSE: DOW), today announced a three-year collaboration to develop novel insecticides for crop protection and urban pests. The collaboration builds upon a successful pilot-scale project in which Cambria rapidly identified a candidate target site for a proprietary Dow AgroSciences insecticide.

"One of the striking characteristics of most commercially successful insecticides is that they act by selectively targeting the function of the invertebrate nervous system," said Leo Liu, M.D., president and chief scientific officer of Cambria. "Elucidating the mode of action of neuroactive insecticides is a natural outgrowth of Cambria's expertise in applied neurogenetics. Cambria's ability to rapidly identify neuronal target sites represents a convincing demonstration of our chemical genetic approach to identifying the molecular targets of biologically active compounds. This multiyear agreement with Dow AgroSciences will leverage our technology platform to help discover the next generation of safe and selective insecticide products."

Under the terms of the agreement, Cambria will analyze a series of insecticidal compounds discovered by Dow AgroSciences. Cambria will apply its technology to identify the mechanism of action of certain compounds and design assays that will be used by Dow AgroSciences to develop novel classes of insecticides for crop protection and urban pests. Dow AgroSciences will provide full research funding to Cambria for this project as well as several undisclosed development and commercialization incentives. In addition, Cambria will select a number of proprietary compounds from Dow AgroSciences's chemical library for Cambria's internal human therapeutic discovery programs. Financial terms were not disclosed.

"Dow AgroSciences is committed to developing the safest and most effective products to control insect pests. Our collaboration with Cambria will enable us to efficiently identify high quality targets, dramatically accelerating the discovery and development of new insecticides of value to agriculture and urban pest management," said Dan Kittle, vice president of research and development at Dow AgroSciences.

**About Cambria Biosciences**

Cambria Biosciences LLC is a drug discovery company dedicated to identifying the next generation of neurotherapeutics, medicines for treating neurological diseases. The Company's approach uses living genetic model systems that faithfully recapitulate disease processes to discover and advance promising leads for drug development. Cambria earns revenues from grants and corporate partnerships that leverage its technology platform for other applications, including public health and biodefense, agriculture, and animal health.

**About Dow Agrosciences**

Dow AgroSciences LLC, based in Indianapolis, Ind., USA, is a global leader in providing pest management and biotechnology products that improve the quality and quantity of the earth's food supply and contribute to the safety, health and quality of life of the world's growing population. Dow AgroSciences has approximately 6000 people in over 50 countries dedicated to its business, and has worldwide sales of more than US \$2 billion. Dow AgroSciences is a wholly-owned subsidiary of The Dow Chemical Company.

*This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the respective company's control which may cause actual results, performance or achievements of that company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by regulatory authorities, and other activities.*

For further information, contact

Cambria Biosciences  
Dr. Leo Liu  
President  
[lliu@cambriabio.com](mailto:lliu@cambriabio.com)  
978-938-1333

MacDougall Biomedical Communications  
Kari Watson  
[kwatson@macbiocom.com](mailto:kwatson@macbiocom.com)  
508-647-0209

Dow Agrosciences, LLC  
Robyn Heine  
317-337-4807